伊塔可纳酸转运体SLC13A3通过赋予铁灭菌耐药性来降低瘤免疫力
Heng Lin1, Kole Tison2, Yuheng Du3
1Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Cancer cell
|November 8, 2024
概括
瘤细胞通过通过SLC13A3传输伊塔科纳酸来抵抗铁亡,从而阻碍了免疫检查点阻塞 (ICB) 治疗. 抑制SLC13A3可以恢复铁,从而提高ICB在癌症中的有效性.
科学领域:
- 免疫代谢过程中的免疫代谢.
- 癌症免疫学 癌症免疫学
- 瘤微环境是一个微环境.
背景情况:
- 免疫检查点封锁 (ICB) 是有前途的,但在许多癌症患者中面临阻力.
- 瘤细胞可以逃避铁亡,这是一种细胞死亡途径,对于瘤微环境 (TME) 内的抗瘤免疫至关重要.
研究的目的:
- 研究瘤中铁灭性耐药性的机制,并确定新的治疗点,以提高ICB的疗效.
主要方法:
- 发现SLC13A3作为瘤细胞中的伊塔康酸转运体.
- 研究了瘤相关巨细胞 (TAM) 和瘤细胞中的SLC13A3-itaconate-NRF2-SLC7A11轴.
- 利用结构建模和分子对接来识别SLC13A3抑制剂 (SLC13A3i).
- 评估了ACOD1删除,SLC13A3废除和SLC13A3i治疗对瘤铁和ICB反应的影响.
主要成果:
- SLC13A3促进瘤细胞从TAM中吸收伊塔康酸盐,激活NRF2-SLC7A11通路,并赋予对免疫媒介铁灭的抵抗力.
- 遗传或药理上抑制SLC13A3,或干扰伊塔科纳酸合成,使瘤对铁亡敏感.
- 针对SLC13A3-itaconate轴抑制了瘤的进展,并提高了ICB治疗的有效性.
结论:
- 在TME中发现了一种新型的免疫介导铁灭抵抗机制,该机制涉及SLC13A3-itaconate-NRF2-SLC7A11轴.
- 在SLC13A3阳性癌症中,SLC13A3是一种有希望的免疫代谢标,可以提高ICB的疗效.
相关概念视频
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
The Early Endosome: Endocytosis of Transferrin
3.2K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.2K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K


